Evidence map›Paper›PMID 16580499›Full record

ArticleInternational journal of radiation oncology, biology, physics2006

Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma.

Joe Y Chang, Xiaochun Zhang, Ritsuko Komaki, Rex Cheung, Bingliang Fang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Therapy-resistant cancer stem cells have differing sensitivity to photon versus proton beam radiation.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2013
    Article
  3. Coxsackie-adenovirus receptor as a novel marker of stem cells in treatment-resistant non-small cell lung cancer.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2012
    Article
  4. Article
  5. Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus.Clinical cancer research : an official journal of the American Association for Cancer Research · 2008
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Joe Y ChangDepartment of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. jychang@mdanderson.org
Xiaochun Zhang
Ritsuko Komaki
Rex Cheung
Bingliang Fang
The University of Texas MD Anderson Cancer Center · US

Funding

Oncolytic adenovector-mediated TRAIL gene therapy for cancersR01CA092487 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FANG, BINGLIANG · 2002 to 2011
$2.4M
Expression of Proapoptotic Genes for Cancer TherapyR01CA098582 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FANG, BINGLIANG · 2003 to 2006
$1.3M
NCI NIH HHS R01 CA092487NCI NIH HHS R01 CA 092487-01A1NCI NIH HHS R01 CA098582NCI NIH HHS R01 CA 098582-01A1
6 · The paper itself

Abstract

purposeTo overcome radiation resistance in esophageal adenocarcinoma by tumor-specific apoptotic gene targeting using tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). METHODS AND MATERIALS: Adenoviral vector Ad/TRAIL-F/RGD with a tumor-specific human telomerase reverse transcription promoter was used to transfer TRAIL gene to human esophageal adenocarcinoma and normal human lung fibroblastic cells (NHLF). Activation of apoptosis was analyzed by Western blot, fluorescent activated cell sorting, and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate labeling (TUNEL) assay. A human esophageal adenocarcinoma mouse model was treated with intratumoral injections of Ad/TRAIL-F/RGD plus local radiotherapy.

resultsThe combination of Ad/TRAIL-F/RGD and radiotherapy increased the cell-killing effect in all esophageal adenocarcinoma cell lines but not in NHLF cells. This combination also significantly reduced clonogenic formation (p < 0.05) and increased sub-G1 deoxyribonucleic acid accumulation in cancer cells (p < 0.05). Activation of apoptosis by Ad/TRAIL-F/RGD plus radiotherapy was demonstrated by activation of caspase-9, caspase-8, and caspase-3 and cleaved poly (adenosine diphosphate-ribose) polymerase in vitro and TUNEL assay in vivo. Combined Ad/TRAIL-F/RGD and radiotherapy dramatically inhibited tumor growth and prolonged mean survival in the esophageal adenocarcinoma model to 31.6 days from 16.7 days for radiotherapy alone and 21.5 days for Ad/TRAIL-F/RGD alone (p < 0.05).

conclusionsThe combination of tumor-specific TRAIL gene targeting and radiotherapy enhances the effect of suppressing esophageal adenocarcinoma growth and prolonging survival.

Indexed as

AdenocarcinomaAdenoviridaeAnalysis of VarianceApoptosisApoptosis Regulatory ProteinsCell Line, TumorCombined Modality TherapyEsophageal NeoplasmsGene TargetingGenetic VectorsHumansMembrane GlycoproteinsRadiation ToleranceSurvival AnalysisTNF-Related Apoptosis-Inducing LigandTumor Necrosis Factor-alphaApoptosis Regulatory ProteinsMembrane GlycoproteinsTNF-Related Apoptosis-Inducing LigandTNFSF10 protein, humanTnfsf10 protein, mouseTumor Necrosis Factor-alpha

Identifiers

PMID16580499
PMCPMC1458528
OpenAlexW1976728948

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.